FR104

2 Cited Publications
Customer Review

Based on 2 publication(s) in Google Scholar

FR104 is a selective CD28 inhibitor (binding to CD28 with a Kd value of 4.6 nM; ED50 value of 7.5 ng/mL). FR104 blocks the binding of CD28 to CD80/CD86 and ICOSL, inhibiting conventional T cell costimulation, proliferation, IL-2 secretion, alloantigen responses, and donor-specific alloantibody production. FR104 does not affect the CTLA-4/PD-L1 pathway, preserves the suppressive function of regulatory T cells, and accumulates Helios-negative Foxp3-positive regulatory T cells. FR104 has a prolonged half-life via pegylation (PEG300) (HY-Y0873) and sustained receptor occupancy, and alleviates central nervous system inflammation, demyelinating lesions, and anti-rhMOG responses. FR104 can be used for research on graft-versus-host disease, renal allograft rejection, and experimental autoimmune encephalomyelitis.

For research use only. We do not sell to patients.

  • Purity : 97.26%
  • Molecular Weight:145.08 kDa
  • Storage:
    Shipping with dry ice

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) FR104

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00